David Mehalick - Coeptis Therapeutics Chairman, CoFounder
| COEPW Stock | USD 0.02 0.00 0.00% |
Insider
David Mehalick is Chairman, CoFounder of Coeptis Therapeutics Holdings
| Age | 55 |
| Address | 105 Bradford Road, Wexford, PA, United States, 15090 |
| Phone | 724 934 6467 |
| Web | https://coeptispharma.com |
David Mehalick Latest Insider Activity
Tracking and analyzing the buying and selling activities of David Mehalick against Coeptis Therapeutics stock is an integral part of due diligence when investing in Coeptis Therapeutics. David Mehalick insider activity provides valuable insight into whether Coeptis Therapeutics is net buyers or sellers over its current business cycle. Note, Coeptis Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Coeptis Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
David Mehalick over six months ago Bona fide gift to David Mehalick of 700000 shares of Coeptis Therapeutics subject to Section 16 | ||
David Mehalick over a year ago Acquisition by David Mehalick of 250000 shares of Coeptis Therapeutics subject to Rule 16b-3 |
Coeptis Therapeutics Management Efficiency
The company has return on total asset (ROA) of (2.4555) % which means that it has lost $2.4555 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (14.497) %, meaning that it generated substantial loss on money invested by shareholders. Coeptis Therapeutics' management efficiency ratios could be used to measure how well Coeptis Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to climb to -3.66 in 2024. Return On Capital Employed is likely to climb to -4.02 in 2024. At this time, Coeptis Therapeutics' Total Assets are fairly stable compared to the past year. Total Current Assets is likely to climb to about 4.8 M in 2024, whereas Intangible Assets are likely to drop slightly above 37.2 K in 2024.Similar Executives
| Found 2 records | INSIDER Age | ||
| Gary Conte | Coeptis Therapeutics | N/A | |
| Daniel Yerace | Coeptis Therapeutics | 41 | |
Management Performance
| Return On Equity | -14.5 | ||||
| Return On Asset | -2.46 |
Coeptis Therapeutics Leadership Team
Elected by the shareholders, the Coeptis Therapeutics' board of directors comprises two types of representatives: Coeptis Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Coeptis. The board's role is to monitor Coeptis Therapeutics' management team and ensure that shareholders' interests are well served. Coeptis Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Coeptis Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christine Sheehy, CFO CoFounder | ||
| Daniel Yerace, VP CoFounder | ||
| Gary Conte, VP Marketing | ||
| David Mehalick, Chairman, CoFounder |
Coeptis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Coeptis Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -14.5 | ||||
| Return On Asset | -2.46 | ||||
| Number Of Shares Shorted | 12.1 K | ||||
| EBITDA | (36.35 M) | ||||
| Net Income | (37.57 M) | ||||
| Total Debt | 1.71 M | ||||
| Book Value Per Share | 0.06 X | ||||
| Cash Flow From Operations | (3.88 M) | ||||
| Beta | -0.59 | ||||
| Total Asset | 7.92 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Coeptis Stock Analysis
When running Coeptis Therapeutics' price analysis, check to measure Coeptis Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coeptis Therapeutics is operating at the current time. Most of Coeptis Therapeutics' value examination focuses on studying past and present price action to predict the probability of Coeptis Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coeptis Therapeutics' price. Additionally, you may evaluate how the addition of Coeptis Therapeutics to your portfolios can decrease your overall portfolio volatility.